Skip to content
OVCAR-8-Luc
Tissue
Ovary
Disease
Adenocarcinoma
Metastatic site
Primary tumor site (ovary)
Synonyms
OVCAR 8, NIH:OVCAR-8, OVCAR8, Ovcar8, OVCAR.8, OVCA8, OVCAR-8/EGFP_LC3

Documents

OVCAR-8-Luc

Cell line · Product number 305697

OVCAR-8-Luc cells are a bioluminescent derivative of the human ovarian adenocarcinoma cell line OVCAR-8, which was originally established from an adult pa...

CA$800.00excl. tax and shipping
In stock
Lot
Recommended (freshest lot)
  • CoA
  • CoA
1

01General information

Description

OVCAR-8-Luc cells are a bioluminescent derivative of the human ovarian adenocarcinoma cell line OVCAR-8, which was originally established from an adult patient with advanced-stage disease. These cells have been genetically engineered to stably express luciferase, an enzyme that catalyzes light emission in the presence of its substrate, enabling highly sensitive, non-invasive monitoring of cellular activity. The parental OVCAR-8 line is characterized by aggressive growth, genomic instability, and features representative of high-grade serous ovarian cancer, making it a widely used model for studying ovarian tumor biology.

The incorporation of luciferase allows OVCAR-8-Luc cells to be used in longitudinal in vivo imaging applications, particularly in xenograft and orthotopic tumor models, where tumor burden and metastatic dissemination can be quantitatively tracked over time using bioluminescence imaging. These cells retain key molecular and phenotypic traits of the parental line, including alterations in pathways relevant to ovarian cancer progression such as p53 dysfunction and dysregulated cell cycle control. Consequently, OVCAR-8-Luc cells are well suited for evaluating therapeutic efficacy, tumor growth kinetics, and metastatic behavior, as well as for studying tumor microenvironment interactions in preclinical research.

Tissue
Ovary
Disease
Adenocarcinoma
Metastatic site
Primary tumor site (ovary)
Applications
Ovarian cancer research; bioluminescence imaging in xenograft/orthotopic models; in vivo tumor burden tracking; drug efficacy and pharmacodynamics; PARP inhibitor and platinum sensitivity studies; peritoneal metastasis modeling; ovarian cancer immunotherapy evaluation
Synonyms
  • OVCAR 8
  • NIH:OVCAR-8
  • OVCAR8
  • Ovcar8
  • OVCAR.8
  • OVCA8
  • OVCAR-8/EGFP_LC3

02Classification

Organism
Human
Sex
Female
Growth properties
Adherent
GMO status
GMO-S1
GMO status details
GMO-S1: This cell line contains a stably integrated firefly luciferase reporter cassette (Luc2, codon-optimized) introduced via replication-incompetent lentiviral transduction. The resulting polyclonal cell population was maintained under puromycin selection (1–5 µg/mL). S1 containment is required. This classification applies only within Germany and may differ elsewhere.
Biosafety level
1

03Characteristics

Morphology
Epithelial-like
Cell type
Epithelial cells

04Identifiers

Citation
OVCAR-8-Luc (Cytion catalog number 305697)
NCBI TaxID
9606
Cellosaurus
CVCL_2169

05Expression and susceptibility

Antigen expression
Luc2 (firefly, codon-optimized)

06Handling and culture

Culture medium
RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
Incubation atmosphere

37°C, 5% CO2, humidified atmosphere.

Supplements
Supplement the medium with 10% FBS
Dissociation reagent
Accutase
Seeding density
1-3 x 104 cells/mL
Fluid renewal
2 to 3 times per week
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.

  7. Follow the procedure described under Post-Thaw Recovery

07Quality control and cryopreservation

Freeze medium
As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability.
Storage conditions

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Shipping conditions

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

08Donor

Donor age
64 years
Ethnicity
Caucasian